BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25866685)

  • 1. Nelarabine associated myotoxicity and rhabdomyolysis.
    Haider M; Rizvi SA; Kasi PM
    Case Rep Hematol; 2015; 2015():825670. PubMed ID: 25866685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report.
    Utsumi A; Goto Y; Suzuki T; Imai C; Matsui S; Sakaida E; Ishii I
    J Pharm Health Care Sci; 2022 Jun; 8(1):17. PubMed ID: 35690835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
    Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nelarabine-associated reversible Guillain-BarrĂ©-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
    Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
    Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nelarabine in the treatment of refractory T-cell malignancies.
    Roecker AM; Stockert A; Kisor DF
    Clin Med Insights Oncol; 2010 Dec; 4():133-41. PubMed ID: 21151585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
    Reilly KM; Kisor DF
    Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
    Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
    Shimony S; DeAngelo DJ; Luskin MR
    Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
    Cooper TM
    Ther Clin Risk Manag; 2007 Dec; 3(6):1135-41. PubMed ID: 18516261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
    Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
    Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
    Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
    Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.